Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes repigmentation and curling of hair in a patient undergoing acitretin therapy.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

This review examines drug repositioning as a strategy for combating bacterial infections, highlighting its potential to address multidrug-resistant strains and antibiotic resistance by analyzing safety profiles, synergistic combinations, and promising results for drugs initially used for other conditions.

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This article discusses the potential for combining PROTACs with other therapeutic modalities in drug discovery and reports no clinical results.

This review discusses drug repurposing strategies for rare diseases, highlighting methodologies, achievements, and challenges, but reports no new clinical results.

This study suggests that among GLP-1 agonists, liraglutide and exenatide are linked to the highest rates of gastrointestinal issues, including potentially pancreatitis-related enzyme changes noted in animal models.

In this study, valproic acid, levetiracetam, and phenytoin were the main anti-seizure medications associated with adverse drug reactions in pediatric epilepsy patients, with younger children and those on polytherapy at higher risk.

This case study reports that a 15-year-old male with multiple autoimmune conditions showed significant improvement in skin and gastrointestinal symptoms, along with hair regrowth, after 16 weeks of treatment with the JAK-1 inhibitor upadacitinib, demonstrating its potential in managing complex autoimmune disorders.

Upadacitinib effectively treats pyoderma gangrenosum.

In this case study, a 29-year-old man with alopecia areata experienced satisfactory hair regrowth after five months of combined intralesional triamcinolone acetonide and platelet-rich plasma therapy.

This report highlights Amvuttra's approval for hATTR amyloidosis as a more convenient RNAi therapy, and Olumiant's attention as the first systemic drug for hair loss among recent developments.

Platelet-rich plasma doesn't prevent hair loss from chemotherapy, and mononuclear cells only help against hair loss from one specific chemotherapy drug.

This article reviews pivotal trials and recent findings in chemoprevention for breast, prostate, and colorectal cancers, emphasizing its potential and the importance of further research, public education, and partnerships, but reports no new results.

In this study, divalproex sodium extended-release was found to be more tolerable and preferred by patients compared to the delayed-release formulation, with improved seizure control and psychiatric symptom relief.

In this study, patients with epilepsy who switched from immediate-release to extended-release divalproex sodium did not experience significant changes in seizure frequency, but most preferred the new formulation due to a subjective decrease in tremor during daily activities.

Haloperidol decanoate can cause alopecia areata.

This study reports significant hair regrowth in two alopecia areata patients resistant to intralesional corticosteroids after treatment with intralesional polydeoxyribonucleotide.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

In this study, peptide-based nanoparticles were successfully used to deliver the CRISPR-Cas9 system into cancer cells, effectively targeting and editing KRAS mutations, suggesting promising therapeutic potential for cancer treatment.

In this article, the authors describe how drug repurposing, supported by large-scale data and artificial intelligence, can make drug discovery more cost-effective and expedient compared to traditional methods, despite certain regulatory challenges.

This review discusses valproic acid as a common antiseizure medication associated with alopecia and highlights the need for its inclusion in relevant medical guides, without presenting new clinical findings.

This study demonstrates that pH-responsive nanogels designed with comb-like anionic polymers significantly improved oral delivery of the chemotherapy drug camptothecin, enhancing drug stability in acidic conditions and release in the intestines, with increased cellular uptake and cytotoxic effects against colorectal carcinoma cells.

This review hypothesizes that risperidone long-acting injectable may be linked to bullous pemphigoid in a bipolar patient, though current studies report mixed results.

This review discusses surgical factors that may increase the risk of developing complex regional pain syndrome and describes potential preventive techniques but presents no new clinical results.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

This case report observed alopecia universalis, a complete hair loss condition, in a patient during a clinical trial with the angiotensin receptor-neprilysin inhibitor sacubitril/alisartan, indicating that ARNI therapy might be associated with such cutaneous reactions.